Official and authoritative background links used for intake education.
Evidence-informed medication review
Dupixent medication and treatment records checklist
This intake path helps organize Dupixent use, the condition treated, reported side effects, treatment timing, and supporting medical records. It does not provide a medical diagnosis or decide legal eligibility.
Dupixent Lawsuit Overview
Lawsuits are being filed against Sanofi and Regeneron, the manufacturers of Dupixent (dupilumab), alleging that the drug causes or accelerates T-Cell Lymphoma, specifically Cutaneous T-Cell Lymphoma (CTCL). The first wrongful death lawsuit was filed in October 2025, involving a patient who died from T-cell lymphoma shortly after starting the treatment.
Plaintiffs claim that the manufacturers failed to warn doctors and patients about these risks despite growing evidence. Studies have shown a significant increase in lymphoma risk for Dupixent users, yet the drug's warning label does not currently include T-cell lymphoma as a potential side effect.
What Is Dupixent?
Dupixent (dupilumab) is an FDA-approved prescription biologic used to treat moderate-to-severe eczema (atopic dermatitis), asthma, and chronic rhinosinusitis with nasal polyps. It works by blocking IL-4 and IL-13 proteins to inflammation. However, by suppressing specific immune pathways, it may also suppress the body's natural defense against abnormal cell growth, potentially leading to cancer.
Serious Side Effects: T-Cell Lymphoma
The primary concern in these lawsuits is the development of Cutaneous T-Cell Lymphoma (CTCL), a rare cancer of the immune system that manifests on the skin.
Warning Signs of CTCL
Skin Lesions: Red, scaly patches or thick plaques that may be mistaken for eczema.
Itching & Pain: Persistent discomfort in affected areas.
Swollen Lymph Nodes: A common sign of lymphoma.
Systemic Symptoms: Fatigue, weight loss, and night sweats.
Key Research Findings
Increased Risk: A 2024 study suggests a 300% to 350% higher risk of CTCL in Dupixent users.
Rapid Progression: Case reports describe patients whose cancer accelerated rapidly after starting the drug.
Misdiagnosis: Doctors may mistake early cancer signs for worsening eczema, delaying life-saving treatment.
Eligibility Criteria to File a Claim
If you developed T-Cell Lymphoma after taking Dupixent, you may be entitled to compensation for medical bills, lost wages, and pain and suffering.
You typically qualify if you:
Used Dupixent (dupilumab) as prescribed for conditions like eczema or asthma.
Were subsequently diagnosed with T-Cell Lymphoma or Cutaneous T-Cell Lymphoma (CTCL).
Suffered from worsening skin symptoms that were later confirmed to be cancer.
Are a family member of a patient who passed away from lymphoma linked to Dupixent use.
Dupixent Lawsuit FAQs
Lawsuits allege that Dupixent (dupilumab) makers, Sanofi and Regeneron, failed to warn patients and doctors that the drug could cause or accelerate T-cell lymphoma, particularly Cutaneous T-Cell Lymphoma (CTCL), or worsen existing hidden cancers.
Warning signs include red, scaly patches or thick plaques on the skin, itching or pain in affected areas, swollen lymph nodes, fatigue, and weight loss. In some cases, these symptoms may be mistaken for worsening eczema.
Yes. Several 2024 and 2025 studies have found a significant increase in CTCL risk among Dupixent users. A 2025 study led by Sheng-Kai Ma found a more than 4.5 times higher risk of CTCL in asthma patients using dupilumab compared to other treatments.
You may be eligible if you used Dupixent as prescribed and were subsequently diagnosed with T-Cell Lymphoma, especially CTCL. Surviving family members of patients who died from these conditions may also file a wrongful death claim.
Private case review
Dupixent Lawsuit
Answer the questions below. Your submission is private and does not guarantee case acceptance.
Free to submitNo obligationConsent required before submission
Evidence-informed medication review
Campaign guidance, records, and sources
Review the supporting information below before or after completing the private campaign form.
A practical checklist to help organize useful details before review.
Reviewed for intake accuracy by AMMS Compliance Team
Records and details that may help
- Prescription, dose, and treatment dates
- Condition for which Dupixent was prescribed
- Records of the reported reaction, diagnosis, or treatment
- Prescriber, specialist, hospital, and pharmacy information
Sources used for intake education
These official references are provided for background education only. They do not replace medical or legal advice.
- FDA Dupixent prescribing informationFDA-approved labeling describing current indications, warnings, and adverse reactions.
1. Submit the intake form
Share your contact details and answer the existing campaign-specific questions.
2. Organize supporting details
Gather the records, dates, communications, and other details listed for this campaign.
3. Intake follow-up
AMMS or an authorized intake partner may contact you for missing or clarifying details.
4. Legal review if appropriate
Qualified legal professionals decide whether a claim can move forward. AMMS does not provide legal advice or guarantee results.
Frequently asked questions
Does a reported side effect mean I have a legal claim?
No. An intake review gathers facts. Medical and legal professionals must assess causation, timing, and eligibility.
Can AMMS advise whether I should continue treatment?
No. Medication decisions should be made with a qualified healthcare professional.
Related AMMS resources
AMMS Legal Intake Research TeamReviewed for intake accuracy by AMMS Compliance TeamLast reviewed: 09/16/2026
Important: AMMS provides intake and educational information. We are not providing medical or legal advice on this page, and submitting a form does not create an attorney-client relationship. Case value, eligibility, filing deadlines, and legal strategy must be reviewed by qualified professionals.